Have a feature idea you'd love to see implemented?
Let us know!
ALEC Alector Inc
Price (delayed)
$3.94
Market cap
$385.85M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.7
Enterprise value
$381.79M
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system
Highlights
The debt has contracted by 14% YoY and by 4.1% from the previous quarter
ALEC's EPS is up by 6% from the previous quarter
ALEC's gross profit is down by 36% YoY but it is up by 11% from the previous quarter
The revenue has declined by 36% year-on-year but it has increased by 11% since the previous quarter
The equity has decreased by 27% YoY and by 21% QoQ
The quick ratio has contracted by 17% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of ALEC
Market
Valuations
Earnings
Shares outstanding
97.93M
Market cap
$385.85M
Enterprise value
$381.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.22
Price to sales (P/S)
6.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.21
Revenue
$61.51M
EBIT
-$156.66M
EBITDA
-$147.64M
Free cash flow
-$222.26M
Per share
Balance sheet
Liquidity
EPS
-$1.7
Free cash flow per share
-$2.28
Book value per share
$1.22
Revenue per share
$0.63
TBVPS
$5.29
Total assets
$516.02M
Total liabilities
$397.09M
Debt
$34.64M
Equity
$118.93M
Working capital
$326.84M
Debt to equity
0.29
Current ratio
3.29
Quick ratio
3.22
Net debt/EBITDA
0.03
Margins
Efficiency
Dividend
EBITDA margin
-240%
Gross margin
100%
Net margin
-257.5%
Operating margin
-301.1%
Return on assets
-27%
Return on equity
-108.8%
Return on invested capital
-38.7%
Return on capital employed
-41.9%
Return on sales
-254.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALEC stock price
How has the Alector stock price performed over time
Intraday
4.79%
1 week
-3.08%
1 month
-16.17%
1 year
-18.6%
YTD
-50.63%
QTD
-15.45%
Financial performance
How have Alector's revenue and profit performed over time
Revenue
$61.51M
Gross profit
$61.51M
Operating income
-$185.2M
Net income
-$158.41M
Gross margin
100%
Net margin
-257.5%
ALEC's operating margin has dropped by 82% year-on-year but it is up by 11% since the previous quarter
The net margin has plunged by 75% YoY but it has grown by 11% from the previous quarter
ALEC's gross profit is down by 36% YoY but it is up by 11% from the previous quarter
The revenue has declined by 36% year-on-year but it has increased by 11% since the previous quarter
Growth
What is Alector's growth rate over time
Valuation
What is Alector stock price valuation
P/E
N/A
P/B
3.22
P/S
6.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.21
ALEC's EPS is up by 6% from the previous quarter
The equity has decreased by 27% YoY and by 21% QoQ
ALEC's P/B is 27% below its 5-year quarterly average of 4.4 and 13% below its last 4 quarters average of 3.7
The stock's price to sales (P/S) is 78% less than its 5-year quarterly average of 28.4 and 11% less than its last 4 quarters average of 7.0
The revenue has declined by 36% year-on-year but it has increased by 11% since the previous quarter
Efficiency
How efficient is Alector business performance
ALEC's ROS has plunged by 79% YoY but it is up by 11% from the previous quarter
The return on equity has declined by 45% year-on-year and by 6% since the previous quarter
The return on invested capital has declined by 42% year-on-year and by 4.6% since the previous quarter
Alector's ROA has decreased by 39% YoY and by 5% from the previous quarter
Dividends
What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALEC.
Financial health
How did Alector financials performed over time
ALEC's total assets is 30% greater than its total liabilities
ALEC's total assets is down by 23% year-on-year and by 10% since the previous quarter
ALEC's total liabilities is down by 22% year-on-year and by 5% since the previous quarter
The debt is 71% less than the equity
The equity has decreased by 27% YoY and by 21% QoQ
The debt to equity is up by 21% since the previous quarter and by 16% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.